10:01 AM EST - Aeterna Zentaris Inc. : Announced that, in consultation with The University of Sheffield, UK, Aeterna has selected AEZS-150 as the lead candidate in the Company’s delayed clearance parathyroid hormone fusion polypeptides (DC-PTH) program. Aeterna Zentaris Inc.
shares T.AEZS are trading down $0.04 at $1.12.
